{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.35","value":"1.5"},{"groupId":"OG001","spread":"0.36","value":"0.5"},{"groupId":"OG002","spread":"0.35","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"179"},{"groupId":"OG002","value":"186"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"1.7"},{"groupId":"OG001","spread":"0.37","value":"1.1"},{"groupId":"OG002","spread":"0.37","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"169"},{"groupId":"OG002","value":"172"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.35","value":"2.4"},{"groupId":"OG001","spread":"0.36","value":"1.8"},{"groupId":"OG002","spread":"0.35","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"168"},{"groupId":"OG002","value":"170"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"3.3"},{"groupId":"OG001","spread":"0.38","value":"3.6"},{"groupId":"OG002","spread":"0.38","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"165"},{"groupId":"OG002","value":"165"}],"units":"Participants"}],"title":"Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.36","value":"3.5"},{"groupId":"OG001","spread":"0.36","value":"3.5"},{"groupId":"OG002","spread":"0.36","value":"2.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"161"},{"groupId":"OG002","value":"159"}],"units":"Participants"}],"title":"Cycle 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"3.6"},{"groupId":"OG001","spread":"0.38","value":"3.8"},{"groupId":"OG002","spread":"0.39","value":"2.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"159"},{"groupId":"OG002","value":"134"}],"units":"Participants"}],"title":"Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.35","value":"4.2"},{"groupId":"OG001","spread":"0.36","value":"3.9"},{"groupId":"OG002","spread":"0.37","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"138"},{"groupId":"OG002","value":"130"}],"units":"Participants"}],"title":"Cycle 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.39","value":"3.9"},{"groupId":"OG001","spread":"0.40","value":"3.4"},{"groupId":"OG002","spread":"0.40","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"124"}],"units":"Participants"}],"title":"Cycle 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.40","value":"4.2"},{"groupId":"OG001","spread":"0.42","value":"3.7"},{"groupId":"OG002","spread":"0.41","value":"2.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"119"}],"units":"Participants"}],"title":"Cycle 19"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.40","value":"4.6"},{"groupId":"OG001","spread":"0.41","value":"3.6"},{"groupId":"OG002","spread":"0.40","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"118"}],"units":"Participants"}],"title":"Cycle 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.38","value":"4.1"},{"groupId":"OG001","spread":"0.39","value":"3.6"},{"groupId":"OG002","spread":"0.38","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"95"},{"groupId":"OG002","value":"103"}],"units":"Participants"}],"title":"Cycle 23"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.40","value":"4.1"},{"groupId":"OG001","spread":"0.41","value":"4.4"},{"groupId":"OG002","spread":"0.40","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"96"}],"units":"Participants"}],"title":"Cycle 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.39","value":"4.4"},{"groupId":"OG001","spread":"0.40","value":"4.4"},{"groupId":"OG002","spread":"0.38","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"81"},{"groupId":"OG002","value":"87"}],"units":"Participants"}],"title":"Cycle 27"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.43","value":"4.2"},{"groupId":"OG001","spread":"0.44","value":"4.7"},{"groupId":"OG002","spread":"0.41","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"96"}],"units":"Participants"}],"title":"Cycle 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.41","value":"3.9"},{"groupId":"OG001","spread":"0.42","value":"4.3"},{"groupId":"OG002","spread":"0.40","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"82"}],"units":"Participants"}],"title":"Cycle 31"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.45","value":"4.2"},{"groupId":"OG001","spread":"0.45","value":"4.7"},{"groupId":"OG002","spread":"0.42","value":"3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"89"}],"units":"Participants"}],"title":"Cycle 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.44","value":"4.1"},{"groupId":"OG001","spread":"0.45","value":"4.6"},{"groupId":"OG002","spread":"0.43","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"78"}],"units":"Participants"}],"title":"Cycle 35"}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"206"},{"groupId":"OG002","value":"214"}],"units":"Participants"}],"description":"The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.\n\nChange from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.\n\nDRS was not included in the fixed-sequence testing procedure.","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve \\[AUC\\] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.","id":"OG000","title":"Placebo + Carboplatin + Paclitaxel -> Placebo"},{"description":"Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.","id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel -> Placebo"},{"description":"Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.","id":"OG002","title":"Veliparib + Carboplatin + Paclitaxel -> Veliparib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"HRD population, participants with available data at each time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35","title":"Change From Baseline in Disease Related Symptom (DRS) Score in the HRD Population","type":"SECONDARY","unitOfMeasure":"score on a scale"}